Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

The Impact of Liver Iron Concentration Measurements By Machine-Learned R2 Magnetic Resonance Imaging on Clinical Decision Making in a Cohort of Episodically Transfused Lebanese Patients with Sickle Cell Disease

Adlette Inati, Rita Philippe Zoghby, Avedis Mardirossian, Khaled Baroudi, Kamleh Ibrahim, Tala Elalami Elsabeh, Tim St Pierre, Leila Abas, Antoine Tarabay

Blood (2024) 144 (Supplement 1): 5319.

https://doi.org/10.1182/blood-2024-210484

Published: 2024

Journal Articles

Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease Aged 6 to <12 Years: 2-Year Data from the Phase 2 Solace-Kids Study

Matthew M. Heeney, David C Rees, Slimane Allali, Isaac Odame, Rodolfo D Cançado, Adlette Inati, Elena Cela, Deborah Keefe, Evgeniya Reshetnyak, Velusamy Shanmuganathan Muthusamy, Lidiya Bebrevska, Michele L Nassin, Julie Kanter

Blood (2024) 144 (Supplement 1): 180.

https://doi.org/10.1182/blood-2024-207207

Published: 2024

Journal Articles

Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks

Sophia Delicou, Fuad El Rassi, Biree Andemariam, Miguel R. Abboud, Julie Kanter, Marilyn J. Telen, Jessie Githanga, Adlette Inati, Ibrahim Idris, Sunil Navani, Eric Wu, Andrew Eisenberger

Blood (2024) 144 (Supplement 1): 179.

https://doi.org/10.1182/blood-2024-204962

Published: 2024

Journal Articles

Diagnostic Accuracy of a Fully Automated Method of Analysing MR Images for Evaluation of Liver Iron Concentration in a Population of Thalassemia Major Patients Following Curative Stem Cell Transplantation in Lebanon

Adlette Inati, Nada Sbeiti, Evelyne Khoriaty, Suzan Koussa, Ali T Taher, Therese Abi Nasr, Tim St Pierre

Blood (2023) 142 (Supplement 1): 2467.

https://doi.org/10.1182/blood-2023-185306

Published: 2023

Journal Articles

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Children and Adolescents with Von Willebrand Disease - a Sub-Analysis of Data from the Wil-31 Study

Robert F Sidonio, Jr., Leonid Dubey, Kateryna V Vilchevska, Adlette Inati, Claudia Djambas Khayat

Blood (2023) 142 (Supplement 1): 3992.

https://doi.org/10.1182/blood-2023-180513

Published: 2023

Journal Articles

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Nose Bleeds in Children and Adults with Von Willebrand Disease

Ana Boban, Robert F Sidonio, Jr., Leonid Dubey, Kateryna V Vilchevska, Adlette Inati, Claudia Djambas Khayat

Blood (2023) 142 (Supplement 1): 5509.

https://doi.org/10.1182/blood-2023-180029

Published: 2023

Journal Articles

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results

Blood (2023) 142 (Supplement 1): 271.

https://doi.org/10.1182/blood-2023-187033

Published: 2023

Journal Articles

Trials in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase 1b CROSSWALK-a and Phase 2a CROSSWALK-c Trials - Crovalimab for the Treatment and Prevention of Vaso-Occlusive Episodes in Sickle Cell Disease

Marco Aurelio Salvino, Bulent Antmen, Frederick Chite Asirwa, Satheesh Chonat, Lucia De Franceschi, Perla Eleftheriou, Adlette Inati, Johnny Mahlangu, Erfan Nur, Salvador Payán-Pernía, Asad Charania, Diana Gradinaru, Allison Hsia, Yves Luder, Thomas Perretti, Sasha Srekovic, Pablo Bartolucci

Blood (2023) 142 (Supplement 1): 1158.

https://doi.org/10.1182/blood-2023-179858

Published: 2023

Journal Articles

Effect of Factor VIII and Von Willebrand Factor Activities on Number of Bleeding Events in Previously Treated Patients with Von Willebrand Disease on Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate

Kateryna V Vilchevska, Vladimir Vdovin, Margarita Timofeeva, Claudia Djambas Khayat, Adlette Inati, Robert F Sidonio, Jr.

Blood (2023) 142 (Supplement 1): 5510.

https://doi.org/10.1182/blood-2023-180526

Published: 2023

Journal Articles

Insights into Vaso-Occlusive Crises-Related Readmissions in Patients with SCD across Geographic Regions

Raffaella Colombatti, Carolyn Hoppe, Elliott P. Vichinsky, Mona Hamdy, Adeseye Michael Akinsete, Mark Davis, Halima Bello-Manga, Iheanyi Okpala, Ana Cristina Silva Pinto, Adlette Inati

Blood (2022) 140 (Supplement 1): 5453–5455.

https://doi.org/10.1182/blood-2022-167948

Published: 2022

Journal Articles

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/ Factor VIII Concentrate in Previously Treated Patients with Von Willebrand Disease

Robert F. Sidonio, Jr., Ana Boban, Leonid Dubey, Adlette Inati, Csongor Kiss, Toshko Lissitchkov, Dzmitry Novik, Elina Peteva, Ali T. Taher, Margarita Arkadevna Timofeeva, Kateryna V. Vilchevska, Vladimir Vdovin, Sylvia Werner, Sigurd Knaub, Claudia Khayat

Blood (2022) 140 (Supplement 1): 8438–8439.

https://doi.org/10.1182/blood-2022-162358

Published: 2022

Journal Articles

Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study

Matthew M. Heeney, Miguel R. Abboud, Jessie Githanga, Baba P. D. Inusa, Julie Kanter, Alan D. Michelson, Videlis Nduba, Victor Musiime, Mohini Apte, Adlette Inati, Amar M. Taksande, Marielle Andersson, Magnus Åstrand, Noha Maklad, Mohammad Niazi, Anders Himmelmann, Anders R. Berggren

Blood (2022) 140 (13): 1470–1481.

https://doi.org/10.1182/blood.2021014095

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Effect of Crizanlizumab and Standard of Care (SoC) Versus Standard of Care Alone on Renal Function in Patients with Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)

Santosh L. Saraf, Kenneth I. Ataga, Vimal K. Derebail, Claire C. Sharpe, Adlette Inati, Jeffrey D. Lebensburger, Laurie DeBonnett, Yifan Zhang, Pablo Bartolucci

Blood (2021) 138 (Supplement 1): 3096.

https://doi.org/10.1182/blood-2021-149849

Published: 2021

Journal Articles

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

Elliott Vichinsky, MD, Victor R. Gordeuk, MD, Paul Telfer, DM, FRCP, Adlette Inati, MD FAAP, Margaret Tonda, PharmD, Sarah Gray, PhD, Irene Agodoa, MD, Kenneth I. Ataga, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140863

Published: 2020

Journal Articles

Pharmacokinetics of Ticagrelor in Infants and Toddlers Aged <24 Months with Sickle Cell Disease

Baba PD Inusa, MD, Adlette Inati, MD, Philip Maes, MD, Jessie Githanga, MBChB, MMed, Miguel R. Abboud, MD, Maurizio Miano, Elena Cela, Videlis Nduba, Mohammad Niazi, Magnus Åstrand, Kevin Persson, Anders Rikard Berggren, MD PhD, Glenn Carlson, MD

Blood (2019) 134 (Supplement_1): 1005.

https://doi.org/10.1182/blood-2019-129855

Published: 2019

Journal Articles

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Elliott P. Vichinsky, MD, Paul Telfer, DM, FRCP, Adlette Inati, MD, Margaret Tonda, PharmD, Barbara Tong, PhD, Irene Agodoa, MD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Kenneth I. Ataga, MD

Blood (2019) 134 (Supplement_1): 2313.

https://doi.org/10.1182/blood-2019-129026

Published: 2019

Journal Articles

Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01)

Bart J. Biemond, MD PhD, Anil Tombak, MD, Yurdanur Kilinc, MD, Murtadha Al-Khabori, MD, Miguel R. Abboud, MD, Mohammed Nafea, MD, Adlette Inati, MD, Yasser Ahmed Mohamed Soliman Wali, MD, Jens Kristensen, MD PhD, Ellen Donnelly, PhD, John Ohd, MD PhD

Blood (2019) 134 (Supplement_1): 614.

https://doi.org/10.1182/blood-2019-124653

Published: 2019

Journal Articles

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)

Kenneth I. Ataga, MD, Santosh L. Saraf, MD, Vimal K. Derebail, MD, Claire C. Sharpe, Adlette Inati, MD, Jeffrey D. Lebensburger, DO, MSPH, Laurie DeBonnett, MD, Shirong Zhang, Pablo Bartolucci, MD PhD

Blood (2019) 134 (Supplement_1): 1018.

https://doi.org/10.1182/blood-2019-124823

Published: 2019

Journal Articles

Sickle Cell Disease Burden in North Lebanon

Adlette Inati, MD, Chadi Al Alam, Cristel El Ojaimi, Taghrid Hamad, Hemanth Kanakamedala, Virginia Pilipovic, Ramzieh Sabah

Blood (2019) 134 (Supplement_1): 1022.

https://doi.org/10.1182/blood-2019-128311

Published: 2019

Journal Articles

Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease

Clark Brown, Carolyn Hoppe, Adlette Inati, Miguel R. Abboud, Winfred Wang, MD, Robert Liem, MD, Gerald Woods, Lewis L. Hsu, Victor R. Gordeuk, MD, Connie Piccone, Richard A. Drachtman, Erica Fong, Sandra Dixon, Margaret Tonda, PharmD, Carla Washington, Joshua Lehrer-Graiwer

Blood (2018) 132 (Supplement 1): 509.

https://doi.org/10.1182/blood-2018-99-117510

Published: 2018

NARROW

The Impact of Liver Iron Concentration Measurements By Machine-Learned R2 Magnetic Resonance Imaging on Clinical Decision Making in a Cohort of Episodically Transfused Lebanese Patients with Sickle Cell Disease

Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease Aged 6 to <12 Years: 2-Year Data from the Phase 2 Solace-Kids Study

Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks

Diagnostic Accuracy of a Fully Automated Method of Analysing MR Images for Evaluation of Liver Iron Concentration in a Population of Thalassemia Major Patients Following Curative Stem Cell Transplantation in Lebanon

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Children and Adolescents with Von Willebrand Disease - a Sub-Analysis of Data from the Wil-31 Study

Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Nose Bleeds in Children and Adults with Von Willebrand Disease

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results

Trials in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase 1b CROSSWALK-a and Phase 2a CROSSWALK-c Trials - Crovalimab for the Treatment and Prevention of Vaso-Occlusive Episodes in Sickle Cell Disease

Effect of Factor VIII and Von Willebrand Factor Activities on Number of Bleeding Events in Previously Treated Patients with Von Willebrand Disease on Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate

Insights into Vaso-Occlusive Crises-Related Readmissions in Patients with SCD across Geographic Regions

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/ Factor VIII Concentrate in Previously Treated Patients with Von Willebrand Disease

Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Effect of Crizanlizumab and Standard of Care (SoC) Versus Standard of Care Alone on Renal Function in Patients with Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

Pharmacokinetics of Ticagrelor in Infants and Toddlers Aged <24 Months with Sickle Cell Disease

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Efficacy and Safety of Sevuparin, a Novel Non-Anti-Coagulant Heparinoid, in Patients with Acute Painful Vaso-Occlusive Crisis; A Global, Multicenter Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial (TVOC01)

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)

Sickle Cell Disease Burden in North Lebanon

Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only